Forward PE Ratio: 15.54
The forward PE ratio is 15.54 as of Thursday, July 9, 2026.
Forward PE Ratio (15.54) = Close Price ($229.48) / Consensus Forward EPS ($14.85)
DVA Forward PE Ratio Metrics
FORWARD PE RATIO
15.54
DVA Competitors' Forward PE Ratio
DaVita Inc.
Market Cap
$14.73B
Forward PE Ratio
15.54
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| DaVita Inc. (DVA) | $14.73B | 15.54 |
| Medpace Holdings, Inc. (MEDP)vs › | $15.29B | 31.31 |
| The Cooper Companies, Inc. (COO)vs › | $13.85B | 15.04 |
| Solventum Corporation (SOLV)vs › | $13.15B | 11.50 |
| Align Technology, Inc. (ALGN)vs › | $12.76B | 15.36 |
| Revvity, Inc. (RVTY)vs › | $12.60B | 20.86 |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.21 |
| Zimmer Biomet Holdings, Inc. (ZBH)vs › | $17.26B | 10.32 |
| Molina Healthcare, Inc. (MOH)vs › | $12.09B | 45.00 |
| Baxter International Inc. (BAX)vs › | $11.60B | 11.45 |
Trailing vs Forward
Trailing P/E
23.2
reported TTM EPS
Forward P/E
15.5
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $14.85 implies +49.4% EPS growth vs the reported trailing $9.94.
Forward P/E by Fiscal Year
View All Analyst EstimatesAt today's $229.48 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $14.85 | $14.29 – $15.79 | 4 | 15.5x |
| 2027-12-31 | $17.28 | $16.10 – $18.43 | 4 | 13.3x |
| 2028-12-31 | $18.95 | $18.54 – $19.64 | 1 | 12.1x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
Forward PE Ratio Formula & Definition
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Forward PE Ratio FAQ
- What is the forward PE ratio for DaVita Inc. (DVA)?
- The forward PE ratio for DVA stock is 15.54.
Related Metrics
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Javier J. Rodriguez